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Abstract
Background: This study examined the effect of treatment with a novel biomechanical device on the level of pain
and function in patients with knee OA.
Methods: Patients with bilateral knee OA were enrolled to active and control groups. Patients were evaluated at
baseline, at 4 weeks and at the 8-week endpoint. A novel biomechanical device was individually calibrated to
patients from the active group. Patients from the control group received an identical foot-worn platform without
the biomechanical elements. Primary outcomes were the WOMAC Index and ALF assessments.
Results: There were no baseline differences between the groups. At 8 weeks, the active group showed a mean
improvement of 64.8% on the WOMAC pain scale, a mean improvement of 62.7% on the WOMAC function scale,
and a mean improvement of 31.4% on the ALF scale. The control group demonstrated no improvement in the
above parameters. Significant differences were found between the active and control groups in all the parameters
of assessment.
Conclusions: The biomechanical device and treatment methodology is effective in significantly reducing pain and
improving function in knee OA patients.
The study is registered at clinicaltrials.gov, identifier NCT00457132, http://www.clinicaltrials.gov/ct/show/
NCT00457132?order=1
Background
Osteoarthritis (OA) is a major cause of disability in the
older population [1], affecting nearly 21 million indivi-
duals in the United States alone [2]. Currently there is
no cure for OA and treatment is focused on reducing
pain and improving function [3].
There is a growing awareness of the importance of
biomechanical factors in the pathogenesis and progres-
sion of knee osteoarthritis [4-6]. Studies have demon-
strated a clinical association between loads, such as
lifelong physical work [7], competitive sports [8,9], and
obesity [10], and the formation and progression of
osteoarthritis [11]. These factors, together with the mor-
phological changes in the musculoskeletal system that
occur with age, affect the osteochondral structures
[12-15] and neuromuscular control [16]. Neuromuscular
control plays a significant part in determining the func-
tion and stability of the synovial joint [17] and in med-
iating the biomechanical structure of articular cartilage
[18]. Impairment of the neuromuscular control system
contributes to the pathogenesis of osteoarthritis by alter-
ing joint biomechanics and causing increased cartilage
damage [19,20].
Two main types of non-surgical biomechanical inter-
ventions are available for reducing pain and improving
function in patients with knee osteoarthritis. The logic
behind the first type of intervention is unloading the
diseased articular surface by means of wedge insoles,
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[21-25]. The logic behind the second type of interven-
tion is to improve neuromuscular control for the
affected limb, thereby achieving transition from co-
activation to coordinated motor response [26]. The key
element in this intervention, as in any motor learning, is
repetitive exposure of the individual to the desired
movement experience [27]. The focus is on training
under perturbation in closed kinematic chain move-
ments in which the whole limb, rather than just a single
joint, is regarded as a kinetic functional unit. This
approach, however, showed encouraging results only in
case studies [28]. Recently, a novel foot-worn biomecha-
nical device that incorporates the logic of both types of
non-invasive interventions was examined by Haim et al.
using a three-dimensional gait analysis [29]. This device
has the capability to change the location of the center of
pressure (COP) during walking, hence it can shift the
external forces acting on the body. Furthermore, the
device generates perturbation during movement that
challenges neuromuscular control.
The purpose of the current study is to examine the
effectiveness of an individually calibrated biomechanical
device and treatment methodology that combines the
logic of both interventions for reducing pain and
improving function in knee osteoarthritis patients.
Methods
Study Design and Participants
All patients gave written informed consent before enter-
ing the study. The protocol was approved by the Institu-
tional Helsinki Committee Registry of Assaf Harofeh
Medical Center (Helsinki registration number 44/05 and
NIH clinical trial registration number NCT00457132).
The study was conducted at the Department of Ortho-
pedics. Eligibility was defined as symptomatic bilateral
knee OA of the medial compartment for at least
6 months. All patients fulfilled the American College of
Rheumatology clinical criteria for OA of the knee [30]
and had radiographically assessed osteoarthritis of the
knee according to the Kellgren & Lawrence (K&L) scale
[31]. All patients had a varus knee alignment. Exclusion
criteria were acute septic arthritis, inflammatory arthri-
tis, patients with a history of increased tendency to fall,
patients with a history of knee buckling, lack of physical
or mental ability to perform or comply with the treat-
ment procedure, diabetes mellitus, and patients with a
history of pathological osteoporotic fracture.
The study was conducted between December 2005
and February 2006. In December 2005, a total of 57
patients were allocated to the study by the senior ortho-
pedic surgeon (N.H.) according to the inclusion and
exclusion criteria (Figure 1). Patients that were found
eligible were referred to the administrative secretary of
the clinic. Patients were then asked to choose one of the
two days of the week that were scheduled for the study,
according to their own convenience. One of the days
was designated for the active group treatment and the
other day was designated for the control group treat-
ment. The patients from both groups, the senior ortho-
pedic surgeon, the investigators and the administrative
secretary did not know to which group the patients
were assigned. Only the therapist applying and calibrat-
ing the device knew to which group a patient belonged.
T h r o u g h o u tt h ec o u r s eo ft h es t u d yp a t i e n t sf r o mo n e
group had no knowledge of the patients from other
group. At the first session patients underwent a medical
examination conducted by two orthopedic surgeons
(Y.R. and S.B) who did not know to which of the two
groups the patients were assigned. Following the physi-
cal examination patients were referred to the treatment
room that was located at a separate facility. The physical
therapist who applied the intervention was not aware of
the patients’ medical condition and clinical examinations
results throughout the study.
Interventions
The biomechanical system (Apos system, AposTherapy -
Sports and Medical Technologies Ltd. Herzliya, Israel) is
a device combined with a treatment methodology. The
device is calibrated to the individual patient according
to pathology and motion characteristics. Each patient is
asked to walk away from and then back towards the
therapist. A visual gait evaluation is carried out by the
therapist and the device is appropriately calibrated.
Appropriate calibration is defined as bringing the
damaged joint to a biomechanical alignment that mini-
mizes/eliminates pain by shifting and/or changing the
applied forces and, consequently, altering the pressure
distribution within the joint [26,29]. Together with the
biomechanical perturbations applied through all phases
of the step-cycle (i.e., initial contact, mid-stance and
toe-off), this device enables home-based, dynamic, func-
tional and repetitive training intended to improve neu-
romuscular control.
The device consists of two convex shaped biomechani-
cal elements attached to each of the patient’sf e e t
(Figure 2). One is located under the hindfoot region and
the other is located under the forefoot region. The ele-
ments are attached to the patient’s foot using a platform
in the form of a shoe. The platform is equipped with a
specially designed sole that consists of two mounting
rails that enable flexible positioning of each element
under each region.
The methodology consists of two phases, the first
brings the joint to diminished pain alignment and the
second applies perturbations while walking. In medial
compartment deformity the element under the hindfoot
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the COP in the foot laterally, thereby reducing the mag-
nitude of the adduction moment acting on the knee
joint [29]. This is done until the patient reports minimal
pain during initial contact. The element under the fore-
foot is shifted medially from the baseline position until
the patient reports minimal pain during mid-stance.
Once the desired alignment is achieved, the patient
should report immediate pain relief while walking. Per-
turbation is achieved by walking on two convex shaped
elements that create controlled instability in gait.
Treatment Protocol
Active group
The device was calibrated to each patient after baseline
assessment. Treatment was then initiated and continued
daily for a period of eight weeks, during which the
device was again recalibrated, as necessary, after the
first, third and sixth week. Patients were instructed to
follow a treatment protocol based on walking during
activities of daily living, starting with 10 minutes of
indoor walking each day during the first week and gra-
dually increasing to 30 minutes of daily outdoor walking
by the last week. The patients were told to continue
their daily activities wearing their regular footwear.
Patients were also instructed not to ingest any pain
relief medication, non-steroidal anti-inflammatory drug
or food supplements starting from 10 days before the
study (drug wash-out) except for unmarked acetamino-
phen tablets that had been given to them at the start of
the study as a rescue medication.
Control Group
Patients in the control group were fitted with an identi-
cal foot worn platform that did not include the biome-
chanical elements or the movement rails. Without these,
the shoe is left with a regular rubber sole. We assumed
that once the elements were removed, the shoe acts like
any other walking shoe. They were instructed to follow
the same treatment protocol as the active group and to
not ingest any medication or food supplements apart
from the unmarked rescue medication that had been
given to them. Therefore, for all intents and purposes,
the foot worn platform alone was not intended as a type
of intervention. It was a complete control aside from
the walking routine of the patients. Both the active
group and the control group had exactly the same num-
ber of visits. During the visits in the first, third and
sixth weeks, patients from both groups walked back and
forth along a 12 m line while the physiotherapist techni-
cian monitored them walking and noted observations.
Outcome Measures
We tested the clinical efficacy of a device designed to
reduce pain and improve function in knee osteoarthritis
patients using the Western Ontario and McMaster
Osteoarthritis Index (WOMAC) [32] and the Aggre-
gated Locomotor Function (ALF) [33]. Patients were
told to score the questionnaires according to the pain
and function of their worse knee according to them.
The ALF scale is a sum of mean timed scores (seconds)
of three locomotor functions: time taken to walk
8 meters, time taken to ascend and descend 7 stairs and
time taken to transfer from sitting to standing. The
patients were evaluated three times during the study: at
baseline, at 4 weeks and at the 8-week endpoint. Mea-
surements of the ALF test were made with the patients
barefoot as required by the outcome protocol.
Secondary outcome measures were the SF-36 [34]
health survey and the Knee Society Score [35], the latter
of which includes a physical examination subscale.
Statistical Analysis
T h ec r i t e r i af o rc l i n i c a lr e s p o n s et oat r e a t m e n th a d
been defined by the Outcome Measures in Rheumatol-
ogy Clinical Trials (OMERACT) and Osteoarthritis
Research Society International (OARSI). They are either
an improvement in pain or in function of at least
50 percent with a decrease of 2.0 cm on the visual-
analogue-scale (VAS) for pain or function, or an
improvement in both pain and function of at least
20 percent with a decrease of 1.0 cm on the VAS [36].
The trial was designed to have 80% power with a two-
sided p = 0.05 level to detect a mean difference of
2.0 cm (corresponding to means of 2.0 cm versus
4.0 cm and the common within-group standard devia-
tion of 2.5 cm) on the WOMAC VAS scale (0-10 cm),
and a difference of -10.0 sec (corresponding to means of
30.0 sec versus 40.0 sec and the common within-group
standard deviation of 10.0 sec) on the ALF scale.
Figure 1 Patient flow-chart.
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we recruited 57 patients to accommodate the needed
sample size for each of the two groups. The sample size
was defined according to a power calculation that tested
(2-tailed) the null hypothesis that the two population
means were equal (i.e., that the study will have power of
86.1% and 96.8% for WOMAC and ALF, respectively, to
yield a statistically significant result).
To avoid various misleading artifacts we checked our
hypotheses based on the intention to treat (ITT) analy-
sis. In order to reject baseline differences between the
groups we examine the hypothesis that the two groups
were comparable at baseline by using an independent
(2-tailed) t-test on patient age, sex, Kellgren & Lawrence
grade and the baseline scores of all four outcomes.
Changes within the groups and differences between the
groups in primary and secondary outcomes were calcu-
lated by repeated measures ANOVA, which produced
three tests of significance: difference in changes over
time between groups, total changes over time and differ-
ence between groups in general. These three tests are
appropriate for examining our hypothesis that assumes:
a) clinically significant improvement in scale for the
active group; b) no clinically significantly improvement
in scale for the control group; c) no advantage in scale
at baseline for the active group compared to the control
group. The analysis was performed by an external statis-
tician using SPSS software (SPSS, Chicago).
Results
Participants
Of the 57 patients participating in the study, 31
(8 males, 23 females, aged 64 ± 8.1 years) were assigned
to the active group and 26 (7 males, 19 females, aged
66.03 ± 7.8 years) to the control group. Three patients
were lost to follow-up, leaving 29 patients in the active
group and 25 patients in the control group available for
analysis (Figure 1). The patient characteristics and base-
line results for measured variables were similar between
both groups. The study population characteristics are
presented in Table 1.
Clinical Outcomes
A tt h e8 - w e e ke n d p o i n tt h eW O M A Cp a i ns c o r ea n d
function score revealed significant differences between
the groups over time (Time by treatment interaction,
Figure 2 The biomechanical device. (a) Bio-mechanical device comprising of two individually calibrated elements and a foot-worn platform
which they are attached to under the hindfoot and forefoot regions. (b) Bio-mechanical elements are available in different degrees of convexity
and resilience; (c) Height versatile base with 0.25 mm increments; (d) Specially designed sole includes two mounting rails and positioning matrix
to enable flexible positioning of each bio-mechanical element.
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relief after 8 weeks of treatment with a mean difference
of 3.5 cm (64.8%) and a 95% confidence interval ranging
between 2.7-4.4. In contrast, the control group reported
no pain relief, having a mean increase of 0.4 cm (8%)
with a 95% confidence interval ranging between -1.7-0.8.
On the WOMAC function scale, the active group
reported significant improvement with a mean decrease
of 3.2 cm (62.7%) after 8 weeks and a 95% confidence
interval ranging between 2.5-4.1. The control group
reported no function improvement, having a mean
increase of 0.5 cm (9.8%) with a 95% confidence interval
ranging between -1.4-0.5. The extent of improvement in
the level of pain and function corresponds with the
OMERACT criteria for clinical response to treatment.
Furthermore, the ALF final mean score values demon-
strated significant differences between the groups over
time (p < 0.001). The active group showed significant
improvement in function with a mean decrease of 11.6
sec. (31.4%) and 95% confidence interval ranging
between 8.7-14.5 on the ALF scale after 8 weeks. No
improvement was shown by the control group, having a
mean decrease of 0.7 sec (1.8%) and 95% confidence
interval ranging between -0.9-2.1 after 8 weeks. Table 2
summarises the results.
The two secondary outcomes, SF-36 health survey and
the Knee Society Score, showed significant time by
treatment interaction. That is to say, significant changes
were found within the active group after 4 weeks and
after 8 weeks and significant differences were found
between the groups at 4 weeks and at 8 weeks. Table 3
summarises the results. In addition, no side effects were
reported by any of the patients.
We further investigated the changes in the primary
outcomes and secondary outcomes for both groups in
distribution of age and gender. Time by treatment inter-
action was significant for the active group in the three
measured parameters for gender and age: 1) WOMAC
overall score - males p = 0.009, females p < 0.001,
under the age of 64 p < 0.001, above the age of 64 p <
0.001; 2) ALF overall score - males p < 0.001, females p
< 0.001, under the age of 64 p < 0.001, above the age of
64 p < 0.001; 3) SF-36 overall score - males p = 0.04,
females p = 0.001, under the age of 64 p < 0.001, above
the age of 64 p < 0.001. There was no time by treatment
effect in the control group. Figure 3 illustrate the effect
of the treatment between genders and between ages in
the WOMAC results.
Patients from the control group use more of the rescue
medication given to them at the start of the study than
did the active group. After 4 weeks, the active group as a
whole consumed 145 rescue pills whereas the control
group consumed 281 pills. After 8 weeks, the active
group consumed 128 pills and the control group con-
sumed 366 pills. Overall the active group consumed 273
pills and the control group consumed 647 pills.
Discussion
The results of the current study demonstrate the clinical
efficacy of the individually fitted biomechanical device
and treatment methodology in reducing pain and
Table 1 Patients Characteristics of the Two Study
Groups*
Characteristic Active
(N = 31)
Control
(N = 26)
P Value†
Age 64.0 ± 8.1 66.0 ± 7.8 0.31
Female - no. (%) 23 (74) 19 (73)
Kellgren and Lawrence (K&L)
K&L 2 - no. (%) 3 (10) 7 (27) 0.155
K&L 3 - no. (%) 11 (36) 5 (19)
K&L 4 - no. (%) 17 (55) 14 (54)
Body Mass Index (BMI) 30.3 ± 4.30 29.7 ± 3.79 0.56
* Mean values are presented as mean ± SD
† P values for the difference between the groups’ baseline characteristics.
There were no significant differences between the groups at baseline
Table 2 Mean values and time by treatment interaction
results of primary outcome measures*
Outcome Baseline Follow-up
(4 weeks)
Final
(8 weeks)
P Value†
WOMAC - Pain
Active 5.4 ± 2.7 3.1 ± 2.2 1.9 ± 1.6 <0.001
Control 5.0 ± 2.7 5.1 ± 2.2 5.4 ± 2.7
P Value 0.50 0.002 <0.001
WOMAC - Stiffness
Active 5.7 ± 3.0 3.7 ± 2.5 1.9 ± 2.3 <0.001
Control 5.4 ± 3.3 5.4 ± 3.0 5.2 ± 3.2
P Value 0.67 0.02 <0.001
WOMAC - Function
Active 5.1 ± 2.6 3.1 ± 1.9 1.9 ± 1.5 <0.001
Control 5.2 ± 2.3 5.5 ± 2.2 5.7 ± 2.6
P Value 0.91 <0.001 <0.001
WOMAC - Total Score
Active 5.4 ± 2.6 3.3 ± 2.0 1.9 ± 1.7 <0.001
Control 5.2 ± 2.6 5.3 ± 2.3 5.4 ± 2.6
P value 0.71 0.001 <0.001
ALF Score
Active 36.9 ± 11.5 29.2 ± 8.8 25.3 ± 6.6 <0.001
Control 39.2 ± 16.7 37.7 ± 15.5 38.5 ± 16.3
P value 0.56 0.01 <0.001
* Primary outcome measures: Western Ontario and McMaster Osteoarthritis
Index (WOMAC) questionnaire (0-10 cm Scale) and Aggregated locomotor
function (ALF) (sec.). Mean values are presented as mean ± SD.
† The vertical p-value represent the time by treatment interaction results. This
represents the difference between the groups at different points in time. The
horizontal p-value represents group differences in the three examination
points. This represents the differences in the active group across the three
follow-ups. No significant differences were found in the control group.
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device we describe combines “unloading” [21-23] the
damaged compartment and “perturbation” [27,28] (sti-
mulation) of neuromuscular control, two types of inter-
ventions that are recommended for patients with knee
OA. The interpretation of our results can therefore be
based on earlier works.
Past studies showed and stressed the importance and
efficacy of unloading the diseased articular surface in
patients with knee OA [21-23]. A recent study showed
that the biomechanical device used in this study can not
only accomplish this but can also reduce the external
adduction moment loads acting on the knee joint in
healthy population [29]. Furthermore, Fitzgerald et al.
demonstrated the importance of “perturbation” interven-
tion [26,28]. The purpose of the “perturbation” interven-
tion is to stimulate neuromuscular control of the
affected limb. Lewek et al. explained that the aim is to
shift from global concentric contraction muscle patterns
to a coordinative motor response [4]. This should be
done by repetitive exposure to perturbation in closed
kinematic chain movements.
The key feature of the new device in this study is
repetitive perturbations with diminished pain in the
patient’s own environment and during ADL. The struc-
ture of the biomechanical elements and the treatment
methodology promotes perturbations throughout all
phases of step cycle. The perturbations are repeated
thousands of times during walking and activities of daily
living, influencing the whole kinetic and kinematic
chain. In our study we equipped the device with low
convexity biomechanical elements in order to promote
only mild perturbations and enable the patients to walk
in a controlled manner.
Usually, patients who exercise while they are in pain
adopt pathological patterns and also fail to comply [37].
In the current study, the patients reported diminished
pain or no pain while using the device immediately after
calibration. This relief in pain enabled them to walk
painlessly with the device and presumably reacquire
proper neuromuscular control skills [21-23] and appro-
priate motor patterns that they can maintain when not
using the device. In addition, unlike stationary devices,
the new device enables rehabilitation during the
patient’s daily life activities and in the patient’s environ-
ment, where compliance can be expected to be higher.
The study was designed to be a prospective, double
blind, sham controlled study. Maintaining a sham group
of patients with advanced knee OA for a period longer
than two months is problematic for several reasons.
First, from an ethical aspect, the control group patients
were in pain and without treatment. Second, control
group compliance was expected to lessen after a period
of two months due to pain. As shown and explained
above, the intervention group experienced a significant
reduction in pain and improvement in function. In con-
trast, the control group showed no reduction in pain
and a slight deterioration in function. The lack of
improvement in pain and the deterioration in function
in the control group can be explained when considering
the patient population, exercise extent and their clinical
situation. Our patients had moderate-to-severe knee
osteoarthritis, were not allowed to use NSAIDS and
food supplements, and were asked to follow a treatment
program based on dynamic joint loading without biome-
chanical intervention.
This study lacked randomization in the assignment of
the patients to control and active groups. Although both
t h ea c t i v ea n dt h ec o n t r o lg r o u pw e r es i m i l a ri nt h e i r
characteristics and in the measured variables at baseline,
future studies should implement a randomization proce-
dure in assigning patients to control and active groups.
Patients in our study were told not to consume any
medications aside from the rescue pills given to them at
the start of the study. This was done in order to evalu-
ate the effectiveness of the device as a stand-alone
Table 3 Mean values and time by treatment interaction
results of secondary outcome measures*
Outcome Baseline Follow-up
(4 weeks)
Final
(8 weeks)
P Value†
SF-36 Physical Functioning subscale
Active 46.0 ± 18.6 61.8 ± 19.2 69.2 ± 21.0 P < 0.001
Control 43.7 ± 21.1 36.7 ± 20.9 38.7 ± 22.1
P Value 0.66 <0.001 <0.001
SF-36 Mental Health subscale
Active 57.5 ± 45.3 73.6 ± 38.2 90.8 ± 23.4 0.004
Control 56.0 ± 39.3 42.7 ± 40.3 44.0 ± 39.3
P value 0.90 0.006 <0.001
SF-36 Score Results
Active 56.0 ± 21.1 68.1 ± 17.7 77.1 ± 15.1 <0.001
Control 53.5 ± 18.9 51.1 ± 19.5 48.5 ± 22.1
P value 0.65 0.001 <0.001
Knee Society Score
Knee Score
Active 54.1 ± 17.9 67.0 ± 14.3 78.6 ± 11.6 <0.001
Control 60.3 ± 17.9 62.1 ± 17.8 50.8 ± 17.8
P value 0.44 0.25 <0.001
Knee Function Score
Active 52.6 ± 17.6 61.8 ± 16.8 71 ± 16.8 <0.001
Control 56.0 ± 14.8 56.4 ± 17.0 51.4 ± 16.9
P value 0.20 0.23 <0.001
* Secondary outcome measures: SF-36 Health Survey (0-100 scale) and knee
society score (0-100 scale). Mean values are presented as mean ± SD.
† The vertical p-value represent the time by treatment interaction results. This
represents the difference between the groups at different points in time. The
horizontal p-value represents group differences in the three examination
points. This represents the differences in the active group across the three
follow-ups. No significant differences were found in the control group.
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medications. Since we cannot ask patients to refrain
from taking medications for a long period of time, we
made our study only 8 weeks.
The control group in our study did not demonstrate
any placebo effect. This may be explained in two ways.
First, because according to the protocol the control
group was told to walk with the device even while in
pain, we assumed that this worsened their symptoms
and balanced out any placebo effect. Second, it may be
that any placebo effect only occurred in the first two
weeks and as a result our first evaluation at four weeks
did not capture the placebo effect.
T h er e s u l t so ft h i ss t u d yi n t r o d u c ead e v i c et h a t
resulted in significant reduction of pain and function,
which is the focus of knee OA treatment. As such, this
device and methodology may be a possible treatment for
patients with knee OA. Future studies should examine
the long term effect of the device on patients with med-
ial compartment knee OA and patients with other mus-
culoskeletal pathologies.
Conclusion
Our data show that using the AposTherapy system and
treatment methodology is an effective non-pharmacological
therapy that improves both pain and function in patients
with knee OA.
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